{"id":56185,"date":"2023-04-25T13:07:36","date_gmt":"2023-04-25T11:07:36","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/beigene-announces-goals-focused-on-sustainable-growth-and-workforce-diversity-in-new-esg-report\/"},"modified":"2023-04-25T13:07:36","modified_gmt":"2023-04-25T11:07:36","slug":"beigene-announces-goals-focused-on-sustainable-growth-and-workforce-diversity-in-new-esg-report","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/beigene-announces-goals-focused-on-sustainable-growth-and-workforce-diversity-in-new-esg-report\/","title":{"rendered":"BeiGene Announces Goals Focused on Sustainable Growth and Workforce Diversity in New ESG Report"},"content":{"rendered":"
\n

\nNewly Released Report Details Company\u2019s Progress and Plans for Growing Responsibly<\/i><\/p>\n

<\/a><\/p>\n

BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass.–(BUSINESS WIRE)–$BGNE<\/a> #BTKi<\/a>–BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, announced several new Environmental, Social, and Governance (ESG) goals today, including targets related to carbon emissions and workforce diversity. These goals are outlined in the Company\u2019s newly released \u201cChange Is the Cure: 2022 Environmental, Social and Governance Report.\u201d The report highlights BeiGene\u2019s ESG strategy, the progress the Company has made against past goals, and how it intends to achieve its bold new targets.<\/p>\n

\nThis report comes at a time of tremendous growth for BeiGene, which received U.S. approval for BRUKINSA in chronic lymphocytic leukemia (CLL) in January. The Company is also actively expanding its presence in Europe, Latin America and the U.S., where it is currently building a flagship research and development and manufacturing facility in Hopewell, New Jersey.<\/p>\n

\nWhile BeiGene is growing quickly, it recognizes the need to do so responsibly. Change Is the Cure<\/b> is BeiGene\u2019s ESG strategy, and is centered around five pillars: advancing global health, empowering our people, innovating sustainably, supporting communities and operating responsibly. BeiGene has committed to setting goals for each of these pillars and reporting on progress. The 2022 ESG report is the first comprehensive look at the Company\u2019s progress against these goals, while setting ambitious targets for the future.<\/p>\n

\n\u201cAs a global company we understand that we must do our part to contribute to the health of the environment in the communities where we live and work, to overcome global healthcare inequities, and to embed diversity, equity, inclusion, and belonging (DEI&B) into our corporate culture,\u201d said John V. Oyler, Co-Founder, Chairman and CEO of BeiGene. \u201cThe Change Is the Cure framework ensures that as we grow, we are making business decisions that benefit all our stakeholders and fulfill our mission of making high quality therapies accessible and affordable to more people around the world.\u201d<\/p>\n

\n\u201cOur Change Is the Cure Strategy is enabling us to build a company that is committed to sustainability, supporting our people and good corporate citizenship,\u201d said Christine Riley Miller, Executive Director, Corporate Social Responsibility. \u201cBeiGene is focused on achieving our newly announced goals and setting new ambitious targets as we continue to grow.\u201d<\/p>\n

\nNew Goals for Growing Sustainably<\/i><\/p>\n

\nBeiGene understands that human health and the health of the planet are intrinsically linked. As a company focused on improving health and health equity, it is committed to operating in a way that mitigates environmental impacts.<\/p>\n

\nToday, BeiGene announced that by 2024 it will set quantitative emissions targets for both its direct emissions (Scope 1) and emissions generated from the energy it buys (Scope 2). It will also set a quantitative Scope 3 target by 2025, addressing emissions from third parties throughout the value chain.<\/p>\n

\nTo meet its climate goals, BeiGene is building a strategic roadmap that includes energy efficiency projects and renewable energy purchases.<\/p>\n

\nAchieving Gender Parity in Leadership<\/i><\/p>\n

\nOne of BeiGene\u2019s founding principles is that the best way to grow an innovative company is to hire the best people wherever they may be. The Company now has more than 9,000 employees on 5 continents, including a newly opened office in Brazil.<\/p>\n

\nTo support this global workforce, BeiGene strives to foster an environment and culture that reflects and supports the diverse communities of the patients it serves, and the unique qualities that each colleague brings to the company.<\/p>\n

\nToday, BeiGene announced a goal of achieving gender parity at the Vice President and above levels by 2030\u2014a goal it has already made great strides towards. This goal builds on the gender parity the Company had previously achieved among colleagues below the Vice President level.<\/p>\n

\nAs BeiGene continues to grow, it will maintain its deep commitment to supporting a diverse, talented and engaged global workforce.<\/p>\n

\nKey 2022 ESG Achievements<\/i><\/p>\n

\nIn addition to announcing these and other new goals, BeiGene\u2019s ESG report highlights key achievements from 2022, including:<\/p>\n